Cancer Immunotherapy and Biomarkers

Tumor-immune trajectory context connects static tissue architecture to clinical outcomes

This paper introduces a trajectory-centric framework to model dynamic tumor-immune interactions, showing that treatment-phase TME states predict immunotherapy response better than pre-treatment states.

A TROP2/Claudin Program Mediates Immune Exclusion to Impede Checkpoint Blockade in Breast Cancer

This study identifies TROP2 as a regulator of tight junction-mediated immune exclusion in TNBC, showing that targeting TROP2 enhances anti-PD1 therapy response.

Structural basis of CD28 and CTLA-4 interactions with CD80, CD86, and the CD80-PD-L1 heterodimer on artificial and cellular membranes

This study determines the cryo-EM structures of CD28 and CTLA-4 interacting with B7-family ligands on membranes, revealing how membrane geometry and ligand binding affect immune checkpoint signaling.

Murine models for triple-negative breast cancer with differential responsiveness to immunotherapy

The paper develops two murine TNBC models with differing immunotherapy responses for studying treatment mechanisms and therapies.

SPTBN2 promotes an immunosuppressive tumor microenvironment and cross-resistance to anti-cancer therapies

This study identifies SPTBN2 as a regulator of immunosuppressive tumor microenvironment and cross-resistance to therapies, showing its role in suppressing CAR T-cell efficacy.

Histone methyl-transferase G9a inhibition boosts the efficacy of immune checkpoint inhibitors in experimental hepatocellular carcinoma

This study shows that inhibiting G9a enhances the effectiveness of immune checkpoint inhibitors in hepatocellular carcinoma by improving tumor immunogenicity and T cell infiltration.

B7-H3 Modulates Cell Adhesion and Immune Evasion to Promote Tumor Progression and Natural Killer Cell Resistance in Hepatocellular Carcinoma

This study shows B7-H3 promotes HCC tumor progression by enhancing cell adhesion and immune evasion, particularly by reducing NK cell cytotoxicity.

Dual function of DOT1L suppresses tumor intrinsic immunogenicity in hepatocellular carcinoma

The paper identifies DOT1L as a suppressor of tumor intrinsic immunogenicity using CRISPR screens and shows its inhibition enhances immune response in mice.

IFN-γ Orchestrates Coordinated Immunosuppression in Head and Neck Squamous Cell Carcinoma Through JAK-STAT-IRF8 Signaling: A Transcriptome-Wide Computational Analysis

The paper identifies IFN-γ-driven immunosuppressive mechanisms in HNSC through transcriptome-wide analysis, highlighting JAK-STAT-IRF8 signaling and key mediators like PDCD1LG2 and JAK2.

Spatial polarization of endothelial ICAM-1 governs T-cell exclusion in melanoma

This study identifies endothelial ICAM-1 as a regulator of T-cell exclusion in melanoma by spatially polarizing its expression, and shows that blocking ICAM-1 enhances T-cell infiltration and immunotherapy efficacy.

Spatio-temporal mapping of immune cell dynamics during human sequential lymph node metastasis

This study maps immune cell dynamics during human sequential lymph node metastasis using multi-omics approaches and identifies immune alterations linked to patient survival.

Patchouli alcohol suppresses gastric cancer growth and immune evasion via inhibition of the NF-κB/PD-L1 axis

This study shows that Patchouli alcohol inhibits gastric cancer growth and immune evasion by suppressing the NF-κB/PD-L1 axis, enhancing T-cell cytotoxicity.

Addition of chemotherapy to radiotherapy promotes progenitor-exhausted CD8+ T-cell clonal dominance in head and neck cancer

This study shows that chemoradiotherapy (CRT) in head and neck cancer promotes clonal dominance of progenitor-exhausted CD8+ T-cells compared to radiotherapy alone.

Arginine synthesis pathway and ASS1 play a critical role in mRNA translation reprogramming and ICI resistance in cutaneous melanoma

This study identifies arginine synthesis pathway and ASS1 as key factors in mRNA translation reprogramming and ICI resistance in cutaneous melanoma, showing that targeting ASS1 can restore sensitivity to anti-PD-1.

Systemic Cysteine Elevation Sustains T-Cell Activation to Potentiate PD-1 Blockade

This study shows that systemic cysteine elevation enhances T-cell activation and improves the efficacy of PD-1 blockade in pancreatic cancer.

POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer

The paper identifies MDF, a repair scar linked to POLQ-driven error-prone repair, as a marker of immune-responsive HRD pancreatic cancer with increased neoantigens and favorable clinical outcomes.

Tracking antigen-specific T cell response to cancer immunotherapy

The paper develops a pipeline to identify and track antigen-specific T cell responses to cancer immunotherapy in mice using TCR repertoire analysis.

Therapeutic scheduling of WEE1 inhibition preserves T cell function and promotes immune control of HPV+ tumors

This study shows that intermittent WEE1 inhibition preserves T cell function and enhances immune control of HPV+ tumors through non-cell-autonomous immune activation mechanisms.

Identifying the therapeutic potential of Niclosamide in overcoming IFN-gamma dependent cancer immune evasion in the Tumor Microenvironment

This study identifies Niclosamide as a dual STAT1/STAT3 inhibitor that suppresses PD-L1 expression, reduces cancer stemness, and enhances T cell function in the tumor microenvironment.

The differentiation and functional landscape of tumor-resident CD8⁺ T cells shapes immunity and clinical outcomes in clear cell renal cell carcinoma

The paper identifies three CD8+ T cell subsets in ccRCC and links their differentiation states to clinical outcomes.

Integrated single-cell and spatial transcriptomic analysis of T cell exhaustion and immunometabolic remodeling in HPV-positive oropharyngeal squamous cell carcinoma

This study integrates single-cell and spatial transcriptomics to uncover mechanisms of immune checkpoint resistance in HPV-positive oropharyngeal cancer, identifying a KMT2D-KLF7-PD-L1 axis as a therapeutic target.

Lipid-rich ascites reprograms T cell lipid metabolic transcriptome to drive dysfunction

This paper shows that lipid-rich ascites alters T cell metabolism, leading to dysfunction, and that removing lipids restores T cell function and enhances BiTE therapy.

Temporal Mechanisms of T-Cell Fate Decisions under Immune Checkpoint Blockade Resolved by CanonicalTockySeq

This paper introduces CanonicalTockySeq to analyze T-cell fate decisions over time in immunotherapy, showing that effective treatment correlates with reduced antigen engagement and exhaustion signaling.

Systemic neoantigen-specific T cells reveal central determinants of PD-(L)1 blockade efficacy

The paper identifies coordinated neoantigen-specific CD8 T cell responses as key predictors of PD-(L)1 therapy efficacy in non-small cell lung cancer patients.

Respiratory viral infections prime accelerated lung cancer growth

This study shows that prior respiratory viral infections like SARS-CoV-2 or influenza accelerate lung tumor growth by altering the immune environment and promoting a pro-tumor microenvironment.

CRISPR screens establish regulatory maps of immunosuppressive surface molecules in cancer

The paper uses CRISPR screens to identify regulators of immunosuppressive surface molecules in cancer cells, finding DNAJC13 as a key regulator that enhances T-cell sensitivity and tumor survival.

TET2-mutant clonal hematopoiesis prevents T-cell exhaustion and suppresses cancer metastasis

The paper shows TET2-mutant clonal hematopoiesis reduces cancer metastasis by preventing T-cell exhaustion through DNA methylation changes.

The membrane-associated ubiquitin ligase MARCHF8 promotes cancer immune evasion by degrading MHC class I proteins

This study identifies MARCHF8 as a driver of cancer immune evasion by degrading MHC-I proteins and shows its inhibition enhances antitumor immunity and response to immunotherapy.

MAPK ERK5 Is a Novel Regulator of MHC-I in Cancer Cells

This paper identifies ERK5 as a regulator of MHC-I expression in cancer cells, showing that inhibiting ERK5 increases MHC-I levels and enhances CD8+ T cell-mediated apoptosis.

CEACAM5/6+ Tumor Cells and IL-1β+ Macrophages Drive Resistance to Chemo-immunotherapy in Gastric Cancer

The paper identifies two resistance mechanisms in gastric cancer to chemo-immunotherapy, involving CEACAM5/6+ tumor cells and IL-1β+ macrophages, and suggests them as biomarkers and therapeutic targets.